ADC Therapeutics SA (NYSE:ADCT) is facing a sharp market reaction as investors digest the latest trial results for its cancer drug, Zynlonta. ADCT is feeling the pressure from bearish momentum. View the charts here. Despite promising efficacy data from the ongoing LOTIS-7 trial, including high…
Continue reading...